AstraZeneca Atacand HCT
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA clears combination of the angiotensin-2 receptor antagonist candesartan and the diuretic hydrochlorothiazide Sept. 5 for second-line treatment of hypertension. Candesartan is marketed without hydrochlorothiazide as Atacand
You may also be interested in...
GeNeuro To Tackle Long COVID By Targeting Ancestor Viral Gene Activation
Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.
Executives On The Move: CFO Promoted At Novavax, Gilead Gets New Executive Vice President Of Research
Alpha Cognition, F2G and Immune Pharmaceuticals pick up new CEOs, and there is a new chief medical officer at Gemini Therapeutics.
FDA Guides On Virtual Inspections During COVID-19
Details of how the FDA plans to conduct remote evaluations of manufacturing facilities during the COVID-19 pandemic have been set out in guidance published by the US agency.